A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
The purpose of this pivotal, phase 3, randomized, multicenter study is to compare VB-111 plus bevacizumab to bevacizumab in adult patients with recurrent Glioblastoma.
Glioblastoma
DRUG: VB-111 + bevacizumab|DRUG: Bevacizumab
Overall survival, From date of study entry until the date of death from any cause (up to 10 years)
Progression Free Survival, To be assessed from date of randomization until the date of disease progression, assessed up to 10 years.|Tumor response as measured by RANO Criteria, To be assessed from date of randomization until the date of disease progression, assessed up to 10 years.
The purpose of this pivotal, phase 3, randomized, multicenter study is to compare VB-111 plus bevacizumab to bevacizumab in adult patients with recurrent Glioblastoma.